From the Guidelines
Dizziness is a potential side effect of Upadacitinib (Rinvoq), but the provided evidence does not specifically report its incidence. However, it is essential to consider the overall safety profile of Upadacitinib when evaluating its potential side effects. The evidence provided focuses on the comparative efficacy of advanced therapies for managing moderate-to-severe ulcerative colitis, including Upadacitinib 1. While the study does not directly address the incidence of dizziness associated with Upadacitinib, it highlights the medication's efficacy in achieving clinical remission in patients with ulcerative colitis. Some key points from the study include:
- Upadacitinib has shown likely important benefits in achieving clinical remission compared to other therapies, such as Ustekinumab, Mirikizumab, and Risankizumab 1.
- The study notes that the rates of clinical remission observed with Upadacitinib were 33% and 26% in induction trials, with low placebo rates of 4% and 5% 1.
- The FDA has placed a boxed warning on the therapeutic class of JAK inhibitors, including Upadacitinib, due to concerns about cardiovascular risk in adults aged 50 years with rheumatoid arthritis and at least one cardiovascular risk factor 1. In clinical practice, it is crucial to monitor patients taking Upadacitinib for potential side effects, including dizziness, and to adjust treatment plans as needed to minimize risks and optimize outcomes. If dizziness occurs, patients should be advised to avoid driving or operating heavy machinery and to stay hydrated, changing positions slowly to minimize the risk of falls. Healthcare providers should be contacted if dizziness is severe, persistent, or worsening, as it could indicate other issues or require adjustment of the treatment plan. Given the lack of specific data on the incidence of dizziness associated with Upadacitinib in the provided evidence, it is essential to consult the medication's label or other reliable sources for more detailed information on its safety profile.
From the Research
Incidence of Dizziness Associated with Upadacitinib (Rinvoq)
- The provided studies do not directly report the incidence of dizziness associated with Upadacitinib (Rinvoq) 2, 3, 4, 5, 6.
- However, study 6 analyzed adverse event reports of Upadacitinib to the US Food and Drug Administration, but it does not specifically mention dizziness as one of the reported adverse events.
- Studies 2 and 5 discuss the association of various drugs with dizziness, but they do not provide information on Upadacitinib.
- Study 3 investigates the frequency of dizziness-related diagnoses and prescriptions in a general practice database, but it does not mention Upadacitinib.
- Study 4 reports on the efficacy and safety of Upadacitinib for ulcerative colitis, but it does not mention dizziness as a specific adverse event.
Adverse Events Reported for Upadacitinib
- Study 6 reports that Upadacitinib had a higher proportion of serious adverse events compared to other Janus kinase inhibitors, but it does not specify dizziness as one of these events.
- Study 4 reports on the safety of Upadacitinib, including adverse events such as herpes zoster, hepatic disorders, and neutropenia, but it does not mention dizziness.